ASP2535

ASP2535
Names
	IUPAC name 4-[3-(6-phenylpyridin-3-yl)-5-propan-2-yl-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole
Identifiers
CAS Number	374886-51-8;
3D model (JSmol)	Interactive image;
PubChem CID	9800113;
	SMILES CC(C)C1=NN=C(N1C2=CC=CC3=NON=C32)C4=CN=C(C=C4)C5=CC=CC=C5;
Properties
Chemical formula	C22H18N6O
Molar mass	382.427 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ASP2535 is an inhibitor of the type 1 Glycine transporter.^[1] It could potentially be used in treatement of Alzheimer's disease and schizophrenia.

Potential uses

ASP2535 has been investigated for the treatement of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent.^[1] It could also be used for schizophrenia since lack of NMDA receptor activation has been linked to schizophrenia, since Glycine is required as a co-agonist at NMDA receptors, higher glycine levels may be able to restore normal receptor function.^[2]

References

^ ^a ^b Harada, Katsuya; Nakato, Kazuhiro; Yarimizu, Junko; Yamazaki, Mayako; Morita, Masahiko; Takahashi, Shinji; Aota, Masaki; Saita, Kyoko; Doihara, Hitoshi; Sato, Yuichiro; Yamaji, Takayuki; Ni, Keni; Matsuoka, Nobuya (2012-06-15). "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease". European Journal of Pharmacology. 685 (1–3): 59–69. doi:10.1016/j.ejphar.2012.04.013. ISSN 1879-0712. PMID 22542656.
^ Dhami, Kamaldeep; MacKay, Marnie; Maia-de-Oliveira, Joao Paulo; Hallak, Jaime; Todd, Kathryn; Baker, Glen; Dursun, Serdar (2013-06). "Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide". Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 23 (2): 129–137. doi:10.5455/bcp.20130629042437. ISSN 1017-7833. {{cite journal}}: Check date values in: |date= (help)

[:0-1] Harada, Katsuya; Nakato, Kazuhiro; Yarimizu, Junko; Yamazaki, Mayako; Morita, Masahiko; Takahashi, Shinji; Aota, Masaki; Saita, Kyoko; Doihara, Hitoshi; Sato, Yuichiro; Yamaji, Takayuki; Ni, Keni; Matsuoka, Nobuya (2012-06-15). "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease". European Journal of Pharmacology. 685 (1–3): 59–69. doi:10.1016/j.ejphar.2012.04.013. ISSN 1879-0712. PMID 22542656.

[2] Dhami, Kamaldeep; MacKay, Marnie; Maia-de-Oliveira, Joao Paulo; Hallak, Jaime; Todd, Kathryn; Baker, Glen; Dursun, Serdar (2013-06). "Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide". Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 23 (2): 129–137. doi:10.5455/bcp.20130629042437. ISSN 1017-7833. {{cite journal}}: Check date values in: |date= (help)

[1]

[2]